These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26730525)

  • 21. Iliac crest bone graft donor site pain after anterior lumbar interbody fusion: a prospective patient satisfaction outcome assessment.
    Sasso RC; LeHuec JC; Shaffrey C;
    J Spinal Disord Tech; 2005 Feb; 18 Suppl():S77-81. PubMed ID: 15699810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis.
    Fu R; Selph S; McDonagh M; Peterson K; Tiwari A; Chou R; Helfand M
    Ann Intern Med; 2013 Jun; 158(12):890-902. PubMed ID: 23778906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human bone morphogenetic protein-2 versus iliac crest bone graft in anterior cervical discectomy and fusion: Dysphagia and dysphonia rates in the early postoperative period with review of the literature.
    Riederman BD; Butler BA; Lawton CD; Rosenthal BD; Balderama ES; Bernstein AJ
    J Clin Neurosci; 2017 Oct; 44():180-183. PubMed ID: 28716569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft.
    Dimar JR; Glassman SD; Burkus KJ; Carreon LY
    Spine (Phila Pa 1976); 2006 Oct; 31(22):2534-9; discussion 2540. PubMed ID: 17047540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis.
    Dimar JR; Glassman SD; Burkus JK; Pryor PW; Hardacker JW; Carreon LY
    J Bone Joint Surg Am; 2009 Jun; 91(6):1377-86. PubMed ID: 19487515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2: a prospective study of complications.
    Malham GM; Parker RM; Ellis NJ; Blecher CM; Chow FY; Claydon MH
    J Neurosurg Spine; 2014 Dec; 21(6):851-60. PubMed ID: 25279655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Instrumented one and two level posterolateral fusions with recombinant human bone morphogenetic protein-2 and allograft: a computed tomography study.
    Stambough JL; Clouse EK; Stambough JB
    Spine (Phila Pa 1976); 2010 Jan; 35(1):124-9. PubMed ID: 20042965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up.
    Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
    Spine (Phila Pa 1976); 2013 Jun; 38(13):1128-36. PubMed ID: 23370679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine.
    Burkus JK; Gornet MF; Glassman SD; Slosar PJ; Rosner MK; Deckey JE; Nowak J; Hatcher BM
    Spine (Phila Pa 1976); 2011 Dec; 36(25):2158-67. PubMed ID: 21325990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and outcome of graft resorption in anterior lumbar interbody fusion: using femoral ring allografts and recombinant human bone morphogenetic protein-2.
    Kayanja M; Orr RD
    Spine (Phila Pa 1976); 2014 Mar; 39(5):374-80. PubMed ID: 24299714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of TLIF with rhBMP-2 versus no TLIF and higher posterolateral rhBMP-2 dose at L5-S1 for long fusions to the sacrum with sacropelvic fixation in patients with primary adult deformity.
    Rahman RK; Buchowski JM; Stephens B; Dorward IG; Koester LA; Bridwell KH
    Spine (Phila Pa 1976); 2013 Dec; 38(26):2264-71. PubMed ID: 24108280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion.
    Singh K; Nandyala SV; Marquez-Lara A; Cha TD; Khan SN; Fineberg SJ; Pelton MA
    Spine J; 2013 Sep; 13(9):1118-25. PubMed ID: 24029138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accelerating lumbar fusions by combining rhBMP-2 with allograft bone: a prospective analysis of interbody fusion rates and clinical outcomes.
    Slosar PJ; Josey R; Reynolds J
    Spine J; 2007; 7(3):301-7. PubMed ID: 17482113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does recombinant human bone morphogenetic protein-2 use in adult spinal deformity increase complications and are complications associated with location of rhBMP-2 use? A prospective, multicenter study of 279 consecutive patients.
    Bess S; Line BG; Lafage V; Schwab F; Shaffrey CI; Hart RA; Boachie-Adjei O; Akbarnia BA; Ames CP; Burton DC; Deverin V; Fu KM; Gupta M; Hostin R; Kebaish K; Klineberg E; Mundis G; O'Brien M; Shelokov A; Smith JS;
    Spine (Phila Pa 1976); 2014 Feb; 39(3):233-42. PubMed ID: 24477081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: a cohort controlled study.
    Carragee EJ; Mitsunaga KA; Hurwitz EL; Scuderi GJ
    Spine J; 2011 Jun; 11(6):511-6. PubMed ID: 21612985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion.
    Glassman SD; Dimar JR; Carreon LY; Campbell MJ; Puno RM; Johnson JR
    Spine (Phila Pa 1976); 2005 Aug; 30(15):1694-8. PubMed ID: 16094268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complications with recombinant human bone morphogenetic protein-2 in posterolateral spine fusion associated with a dural tear.
    Glassman SD; Gum JL; Crawford CH; Shields CB; Carreon LY
    Spine J; 2011 Jun; 11(6):522-6. PubMed ID: 20598649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Risk of Cancer With the Use of Recombinant Human Bone Morphogenetic Protein in Spine Fusion.
    Dettori JR; Chapman JR; DeVine JG; McGuire RA; Norvell DC; Weiss NS
    Spine (Phila Pa 1976); 2016 Aug; 41(16):1317-1324. PubMed ID: 27261568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) in posterolateral lumbar spine fusion: complications in the elderly.
    Hoffmann MF; Jones CB; Sietsema DL
    J Orthop Surg Res; 2013 Jan; 8():1. PubMed ID: 23317417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion.
    Chen NF; Smith ZA; Stiner E; Armin S; Sheikh H; Khoo LT
    J Neurosurg Spine; 2010 Jan; 12(1):40-6. PubMed ID: 20043763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.